Review Article

Efficacy of Compound Kushen Injection in Relieving Cancer-Related Pain: A Systematic Review and Meta-Analysis

Yu-ming Guo, 1 Yi-xue Huang, 1 Hong-hui Shen, 1 Xiu-xiu Sang, 1 Xiao Ma, 1 Yan-ling Zhao, 1 and Xiao-he Xiao 1,2

1 China Military Institute of Chinese Materia Medica, 302 Military Hospital, Beijing 100039, China
2 Integrative Medicine Center, 302 Military Hospital, Beijing 100039, China

Correspondence should be addressed to Xiao-he Xiao; pharmacy302@126.com

Received 14 May 2015; Accepted 11 June 2015

Academic Editor: Cheryl Hawk

Despite widespread popular use of complementary and alternative medicine (CAM) therapies, a rigorous evidence based on the efficacy of compound kushen injection (CKI) for cancer-related pain is lacking. In this study, we evaluated the efficacy and safety of compound kushen injection and provided information for current or future research and clinical application. Sixteen trials were identified with a total of 1564 patients. The total pain relief rate of CKI plus chemotherapy is better than chemotherapy except for colorectal cancer. The treatment groups achieved a reduction in the incidences of leukopenia and gastrointestinal, hepatic, and renal functional lesion. However, there is paucity of multi-institutional RCTs evaluating compound kushen injection for cancer pain with adequate power, duration, and sham control. The quantity and quality of RCTs are lower so that we still have to boost the research level through scientific design and normative report.

1. Introduction

Pain is the major clinical symptom of cancer patients [1–3]. The management of cancer-related pain is the widespread measure for the patients’ quality of life. However, little management of western medicine can be effective. Analgesics are a mainstay of pain management, but they may cause undesired effects such as sedation, nausea, constipation, and renal or liver toxicity. Complementary and alternative medicine therapies are used widely instead among cancer patients to improve cancer-related pain [4, 5]. However, few studies have been published in English written journals that report the effectiveness and safety of many commonly used traditional Chinese medicine (TCM) therapies.

Compound kushen injection (CKI) was approved for the treatment of cancer by the State Food and Drug Administration of China more than 20 years ago. It was also known as Yanshu injection, which contains extracts from two herbs, kushen (Radix sophorae flavescentis) and baituling (Rhizoma smilacis glabrae). The primary components are oxymatrine and matrine [6]. CKI limited cancer pain both directly by blocking TRPV1 signaling and indirectly by reducing tumor growth [7]. Nowadays, it has been used extensively throughout China for pain treatment in combination with conventional analgesics, chemotherapy, or radiotherapy. In this paper, clinical studies were reviewed to evaluate the efficacy and safety of compound kushen injection for cancer-related pain and provide information for current or future research and clinical application.

2. Methods

2.1. Literature Search. Two independent reviewers, including a librarian, conducted a systematic literature search using databases (MEDLINE, Chinese Biomedical Literature Database, China National Knowledge Infrastructure Database, VIP Database for Chinese Technical Periodicals, Wan-Fang Database, and the Cochrane Library), all from
time of inception up to December 2014. A text word search was done in the title and abstract for each concept and combined with the subject heading searches (cancer or neoplasm [§ indicates truncation], pain, and kushen injection), and then the search was limited to clinical trials. A similar search was done by another investigator independently using PubMed with the search term “cancer pain” and the limits of “clinical trials” and “kushen injection.” Both reviewers also scanned references at the end of articles to manually remove any citations that were obviously irrelevant and also scanned reference lists of the identified articles to identify any additional articles.

2.2. Inclusion and Exclusion Criteria. The inclusion criteria were as follows. (1) Randomized controlled trials (RCTs) of patients with cancer-related pain were selected: the experimental group received compound kushen injection and chemotherapy while control group received chemotherapy only. (2) Outcome assessment included pain-related measurements. (3) No language or blinding restriction was used.

The exclusion criteria were (1) reviews, nonclinical studies, and case observations; (2) no RCTs; (3) controlled interventions with TCM therapies as other Chinese herbs or acupuncture; and (4) inability to find the outcome measurements or duplicated citations.

2.3. Types of Outcome Measures. The primary outcome was total pain relief rate. The reduction in pain intensity was measured using a numerical rating scale (NRS), visual analogue scale (VAS), or verbal rating scale. The secondary outcomes were quality of life and adverse events at the end of treatment course.

2.4. Data Abstraction. The articles that met the inclusion criteria were reviewed by two independent investigators (Yu-ming Guo, and Yi-xue Huang), and relevant data were extracted. Disagreements were resolved by a third reviewer (Xiu-xiu Sang). The methodological quality of RCTs was assessed independently using seven-item criteria according to the Cochrane Collaboration—Cochrane Tool of Risk of Bias. This scale reports adequate sequence generation, allocation concealment, blinding, incomplete outcome data addressed, selective reporting, other biases, and blinding of outcome assessment.

2.5. Data Synthesis and Analysis. Data analyses were performed using the statistical package RevMan 5.0 (Cochrane Collaboration). Dichotomous data were presented as risk ratio (RR) with 95% confidence intervals (CI). Heterogeneity among trials was tested using Q test and considered significant when Q was over 50% or p < 0.1. The random effect model was used for the meta-analysis if there was significant heterogeneity while the fixed effect model was used when the heterogeneity was not significant.

3. Results

3.1. Search Results. A total of 167 references were identified through database searches, of which 151 articles were excluded (36 were not RCTs, 16 did not address the complete data, 5 were associated with other Chinese medicine therapies in experimental group or in control group or with different dosage, 73 did not meet our inclusion criteria for treatment measures, and 21 were with inconsistent criteria), yielding 16 relevant articles for the systematic review and meta-analysis (Figure 1).

3.2. Study Characteristics. A total of 1564 study participants were identified from the 16 trials [8–23] (768 were in the control group, 796 were in the treatment group, and the ages ranged from 18 to 85 years). All studies were conducted in China, published between 2006 and 2014. Fifteen trials [8–17, 19–23] were from single institutions and only 1 trial [18] was multicenter RCT. There were different pain scales used among the 16 trials, with the Numerical Rating Scale being the most common. All of the included studies mentioned randomization, but only 4 trials [16, 18–20] reported the method of random sequences generation. No study mentioned allocation concealment. One [19] report recorded the loss to follow-up, and 2 [15, 18] conducted intention-to-treat analysis. Quality assessment of included randomized controlled trials is shown in Table 1.

Six trials [11, 13, 19–21, 23] compared CKI plus FOLFOX to FOLFOX individually. Four trials [12, 15–17] compared CKI plus NP with NP individually. Four trials [8–10, 18] compared CKI plus TACE with TACE individually. Two trials [14, 22] compared CKI plus GC with GC individually. The duration of studies lasted from 10 days to 18 weeks. All studies used the total pain relief rate as primary outcome. The quality of life was reported in 11 studies [8–10, 12, 15–18, 20–23]. Eight trials [8, 11, 12, 14, 16–18, 22] reported adverse effect. Detailed characteristics of included studies are listed in Table 2.

3.3. Efficacy Assessment

3.3.1. Total Pain Relief Rate. All studies adopted the total pain relief rate to assess the improvement for cancer-related pain. The random effect model was used for statistical analysis because heterogeneity was significant (p < 0.00001, I² = 77%). The combined effects of 16 independent trial results showed that CKI could relieve pain in patients when compared with chemotherapy (n = 1265, RR = 1.69, 95% CI, 1.36 to 2.10, p < 0.00001). The subgroup analysis indicated that no better improvements were observed after CKI treatment for colorectal cancer (Figure 2).

3.3.2. Quality of Life. Karnofsky performance status (KPS) increase rate data extracted from 6 studies [15–17, 20–22] showed heterogeneity among trials (heterogeneity: p = 0.50, I² = 54%). The random effect model was used for statistical analysis. The combined effects of 6 independent trial results showed that CKI had improved the KPS increase rate in patients when compared with chemotherapy alone (n = 420, RR = 1.23, 95% CI, 1.09 to 1.40, p = 0.001) (Figure 3(a)).

KPS scores extracted from 3 studies [9, 10, 18] showed no heterogeneity among trials (heterogeneity: p = 0.68,
Table 1: Quality assessment of included randomized controlled trials.

| Included trials | Random sequence generation | Allocation concealment | Blinding | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other biases |
|-----------------|---------------------------|------------------------|----------|-------------------------------|------------------------|--------------------|--------------|
| CL2014          | Unclear                   | Unclear                | Unclear  | Unclear                       | Yes                    | No                 | Unclear      |
| DL2008          | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Yes          |
| DL2010          | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Unclear      |
| FJW2011         | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Unclear      |
| GJL2007         | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Yes          |
| LYH2011         | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Unclear      |
| LYR2013         | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Unclear      |
| SJ2012          | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Yes          |
| SXW2012         | Yes                       | Unclear                | Unclear  | Unclear                       | No                     | No                 | Unclear      |
| WHJ2006         | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Unclear      |
| WS2014          | Yes                       | Unclear                | No       | Unclear                       | No                     | No                 | Unclear      |
| XJX2013         | Yes                       | Unclear                | Unclear  | Unclear                       | Yes                    | No                 | Unclear      |
| XXD2006         | Yes                       | Unclear                | Unclear  | Unclear                       | No                     | No                 | Yes          |
| YJ2007          | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Unclear      |
| YZG2012         | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Yes          |
| ZJC2012         | Unclear                   | Unclear                | Unclear  | Unclear                       | No                     | No                 | Unclear      |

CBM (n = 176)
CNKI (n = 96)
Wan-Fang (n = 61)
VIP (n = 102)
PubMed (n = 0)
Cochrane Library (n = 0)
Total: 435 records for initial

Records after duplicates removed (n = 435)

Exclusion 204 duplicated citations

Records screen on the title and abstract (n = 231)

Exclusion 64 records irrelevant to the study

Full-text articles for further assessment (n = 167)

Exclusion 36 nonrandomized controlled studies
16 incomplete data
5 Chinese medicine or with different dosage in control
73 not meeting criteria for treatment
21 inconsistent criteria

Eligible studies included for meta-analysis (n = 16)

Figure 1: Flow diagram showing the trial selection process for the systematic review and meta-analysis.
Table 2: Summary of included studies.

| Included trials | Subject (experimental/control) (years; experimental/control) | Type of cancer pain | Intervention | Control | Outcomes |
|-----------------|--------------------------------------------------------------|---------------------|--------------|---------|----------|
| CL2014          | 42/38 Unclear (51 (28–65)/53 (26–66)) Liver cancer          | CKI + TACE          | TACE         | Total pain relief rate |
| DL2008          | 20/20 51 (28–65)/53 (26–66) Liver cancer                   | CKI + TACE          | TACE         | Total pain relief rate; quality of life; adverse events |
| DL2010          | 30/30 51 (37–66)/50 (36–66) Liver cancer                   | CKI + TACE          | TACE         | Total pain relief rate; quality of life |
| FLW2011         | 40/40 66/65 Gastric cancer                                  | CKI + FOLFOX        | FOLFOX       | Total pain relief rate; adverse events |
| GJL2007         | 32/31 60 (43,71) Lung cancer                                | CKI + NP            | NP           | Total pain relief rate; quality of life; adverse events |
| LHY2011         | 83/83 71.4 (60–83)/72.7 (61–85) Gastric cancer              | CKI + FOLFOX        | FOLFOX       | Total pain relief rate |
| LYN2013         | 44/44 52.8 ± 14.5 Lung cancer                               | CKI + GC            | GC           | Total pain relief rate; adverse events |
| SJ2012          | 18/14 62.65 (33,81) Lung cancer                             | CKI + NP            | NP           | Total pain relief rate; quality of life |
| SXW2012         | 54/52 52.5 (32–73)/53.1 (31–72) Lung cancer                | CKI + NP            | NP           | Total pain relief rate; quality of life; adverse events |
| WHJ2006         | 44/43 54 (33,76) Lung cancer                                | CKI + NP            | NP           | Total pain relief rate; quality of life; adverse events |
| WS2014          | 107/104 55.6/54.5 Liver cancer                              | CKI + TACE          | TACE         | Total pain relief rate; quality of life; adverse events |
| XJJX2013        | 60/60 18–75 Gastric cancer                                  | CKI + FOLFOX        | FOLFOX       | Total pain relief rate |
| XXD2006         | 45/44 54 (32,71) Colorectal cancer                           | CKI + FOLFOX        | FOLFOX       | Total pain relief rate; quality of life |
| YJ2007          | 64/62 56 (30–78)/60 (33–75) Colorectal cancer               | CKI + FOLFOX        | FOLFOX       | Total pain relief rate; quality of life |
| YZG2012         | 50/40 56 (40,78)/58 (43,76) Lung cancer                     | CKI + GC            | GC           | Total pain relief rate; quality of life; adverse events |
| ZJC2012         | 33/33 52.3 ± 6.7 Colorectal cancer                           | CKI + FOLFOX        | FOLFOX       | Total pain relief rate; quality of life |

CKI: compound kushen injection; TACE: Transhepatic Arterial Chemotherapy and Embolization; FOLFOX: oxaliplatin + calcium folinate + fluorouracil; NP: Navelbine + cisplatin; GC: gemcitabine + carboplatin.

$I^2 = 0\%$. The fixed effect model was used for statistical analysis. The combined effects of 3 independent trial results showed that CKI had improved the KPS scores in patients when compared with chemotherapy ($n = 311$, RR = 10.07, 95% CI, 8.57 to 11.57, $p < 0.00001$) (Figure 3(b)).

3.3.3. Adverse Events. Specific adverse effects included leukopenia, gastrointestinal adverse reactions, alopecia, hepatic and renal functional lesion, and bone marrow depositions. Of the 16 trials, 8 trials reported adverse effects. The treatment groups achieved a statistically significant reduction in the incidences of leukopenia ($n = 346$, RR = 0.76, 95% CI, 0.64 to 0.90, $p = 0.001$) (Figure 4(a)), gastrointestinal adverse reactions ($n = 238$, RR = 0.39, 95% CI, 0.21 to 0.72, $p = 0.003$) (Figure 4(b)), and hepatic and renal functional lesion ($n = 258$, RR = 0.44, 95% CI, 0.28 to 0.68, $p = 0.0002$) (Figure 4(c)). No severe adverse events were found in the treatment groups.

4. Discussion

Cancer-related pain is the perception of the effect of therapy, disease status, quality of services, and even survival [24]. Intractable cancer pain resistant to World Health Organization (WHO) analgesic ladder afflicts 10–15% of cancer pain patients [25]. Patients used to accept analgesics as per
WHO analgesic ladder but were found to be recalcitrant or developed intolerable side effects limiting their use or dose. CAM is used as an adjunct therapy with standard pain management techniques as it is noninvasive and generally considered to be relatively free of toxicity [26]. CKI is a mixture of natural compounds extracted from kushen and baikuling. It exhibits a variety of pharmacological activities, including anti-inflammatory, antiallergic, antiviral, antifibrotic, and especially anticancer activities [27]. Now with the more and more published RCTs of CKI on cancer-related pain, it is necessary to use the methods of systematic review and meta-analysis to summarize the available evidence and give suggestions to future research and practice. The existing systematic review and meta-analysis assessed the efficacy of CKI only for bone cancer pain or hepatocellular carcinoma [28, 29]. In our study, we used subgroup meta-analysis to evaluate the improvement for cancer-related pain of different organs and assessed the adverse events.

| Study or subgroup | Experimental Events | Experimental Total | Control Events | Control Total | Weight | Risk ratio M-H, random, 95% CI | Risk ratio M-H, random, 95% CI |
|-------------------|--------------------|-------------------|----------------|---------------|--------|-------------------------------|-------------------------------|
| 1.1.1 CKI + FOLFOX versus FOLFOX for gastric cancer | FJW2011 70 40 | 110 | LYG2011 73 46 | 119 | XIX2013 26 35 | 61 | Subtotal (95% CI) 158 154 | 20.1% | 2.19 [1.35, 3.54] |
| Total events | 129 65 | Heterogeneity: $\chi^2 = 0.13; \chi^2 = 6.91, df = 2 (p = 0.03); I^2 = 71\%$ | Test for overall effect: $Z = 3.19$ ($p = 0.001$) |
| 1.1.2 CKI + FOLFOX versus FOLFOX for colorectal cancer | XIX2006 7 9 | 16 | YIZ2007 17 26 | 43 | ZJZ2012 7 13 | 20 | Subtotal (95% CI) 48 44 | 14.5% | 0.94 [0.50, 1.76] |
| Total events | 31 30 | Heterogeneity: $\chi^2 = 0.17; \chi^2 = 5.09, df = 2 (p = 0.08); I^2 = 61\%$ | Test for overall effect: $Z = 0.21$ ($p = 0.84$) |
| 1.1.3 CKI + NP versus NP for lung cancer | GJL2007 25 32 | 57 | SJ2012 16 19 | 35 | SXW2012 32 54 | 86 | WH2006 23 43 | 66 | Subtotal (95% CI) 148 144 | 26.0% | 1.68 [1.33, 2.13] |
| Total events | 96 55 | Heterogeneity: $\chi^2 = 0.00; \chi^2 = 0.70, df = 3 (p = 0.87); I^2 = 0\%$ | Test for overall effect: $Z = 4.37$ ($p < 0.0001$) |
| 1.1.4 CKI + TACE versus TACE for liver cancer | CL2014 28 42 | 70 | DL2008 15 20 | 35 | DL2010 24 30 | 54 | WS2014 45 107 | 152 | Subtotal (95% CI) 199 192 | 21.7% | 2.67 [1.36, 5.26] |
| Total events | 112 40 | Heterogeneity: $\chi^2 = 0.37; \chi^2 = 15.61, df = 3 (p = 0.001); I^2 = 81\%$ | Test for overall effect: $Z = 2.84$ ($p = 0.005$) |
| 1.1.5 CKI + GC versus GC for lung cancer | LYR2013 38 44 | 82 | YZG2012 49 50 | 99 | Subtotal (95% CI) 94 84 | 17.7% | 1.29 [1.12, 1.49] |
| Total events | 87 60 | Heterogeneity: $\chi^2 = 0.00; \chi^2 = 0.04, df = 1 (p = 0.83); I^2 = 0\%$ | Test for overall effect: $Z = 3.48$ ($p = 0.0005$) |
| Total (95% CI) | 647 618 | 100.0% | 1.69 [1.36, 2.10] |

Figure 2: Forest plot of comparison: CKI plus chemotherapy versus chemotherapy alone: total pain relief rate.
One hundred and sixty-seven studies reviewed were CKI plus chemotherapy in treating cancer-related pain. Sixteen trials were identified as eligible studies for systematic review and meta-analysis. The main findings of the present study were that CKI could improve the total pain relief rate and quality of life of patients with cancer-related pain. Despite the apparent positive findings reported, there is insufficient evidence for the effectiveness and safety of CKI as adjuvant therapy for cancer-related pain because the included studies were of generally poor quality and had small sample sizes. Future research should focus on methodologically strong RCTs to determine the potential efficacy of CKI. The CONSORT statement [30] should be used as a guideline when designing and reporting RCTs for TCM in the future.

However, the evidence is limited to make a conclusion on the issue of safety because only 50% of studies mentioned the adverse effects.

**Limitation.** The primary outcome in this review was total pain relief rate. However, the measure through subjective qualitative scores such as “markedly effective,” “effective,” and “ineffective” is not internationally recognized. In addition, the reduction in pain intensity was measured using different scales such as NRS, VAS, and other measures. So it is uncertain in assessing the outcome. No study of the included trials reported whether any adverse events relevant to CKI were apparent in patients. Thus, all adverse events must be reported by the researchers participating in a clinical trial of CKI in the future.

This systematic review and meta-analysis provides moderate evidence for the effectiveness and safety of CKI as adjuvant therapy for cancer-related pain, and a clinical recommendation cannot be warranted because of the generally low methodological quality of the included studies (Table 1). CKI may have beneficial effects in the improvement of total pain relief rate and quality of life and reduction of side effects. However, current evidence is insufficient to support the efficacy of CKI for cancer-related pain because the included studies were of generally poor quality and had small sample sizes. Future research should focus on methodologically strong RCTs to determine the potential efficacy of CKI. The CONSORT statement [30] should be used as a guideline when designing and reporting RCTs for TCM in the future.
Figure 4: Forest plot of comparison: CKI plus chemotherapy versus chemotherapy alone. (a) Incidences of leukopenia; (b) incidences of gastrointestinal adverse reactions; (c) incidences of hepatic and renal functional lesion.

5. Conclusions

CKI appears to be able to improve total pain relief and quality of life and seems to have beneficial effects on reduction of side effects in patients compared with chemotherapy alone.

Disclosure

The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The current work was partially supported by Key Project of the National Natural Science Foundation of China (no. 81330090).

References

[1] S. C. McMillan, M. Tittle, S. Hagan, and J. Laughlin, “Management of pain and pain-related symptoms in hospitalized veterans with cancer,” *Cancer Nursing*, vol. 23, no. 5, pp. 327–336, 2000.

[2] D. Carr, L. Goudas, D. Lawrence et al., “Management of cancer symptoms: pain, depression, and fatigue,” *Evidence Report/Technology Assessment (Summary)*, no. 61, pp. 1–5, 2002.
Evidence-Based Complementary and Alternative Medicine

[3] N. Wells, "Pain intensity and pain interference in hospitalized patients with cancer," Oncology Nursing Forum, vol. 27, no. 6, pp. 985–991, 2000.

[4] E. Ernst and B. R. Cassileth, “The prevalence of complementary/alternative medicine in cancer: a systematic review,” Cancer, vol. 83, no. 4, pp. 777–782, 1998.

[5] M. A. Richardson, T. Sanders, J. L. Palmer, A. Greisinger, and S. E. Singleterry, “Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology,” Journal of Clinical Oncology, vol. 18, no. 13, pp. 2505–2514, 2000.

[6] J. Tian, W.-H. Wang, H.-M. Cao, and Z.-M. Wang, “Determination of matrine, sophoridine and oxymatrine in compound Kushen injection by HPLC,” Zhongguo Zhongyao Zazhi, vol. 32, no. 3, pp. 222–224, 2007.

[7] Z. Zhao, H. Fan, T. Higgins et al., "Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways," Cancer Letters, vol. 355, no. 2, pp. 232–241, 2014.

[8] C. Liang, G. Yanwei, W. Zhiwei et al., “Clinical observation of compound Kushen injection combined with TACE in treatment of liver cancer,” Clinical Chinese Journal of Information on TCM, vol. 21, no. 6, pp. 98–99, 2014.

[9] D. Li, L. Zhuangwei, W. Yiting et al., “Efficacy of compound kushen injection by continuously intravenous infusion combined with TACE in treating middle-and-late stage primary liver cancer,” in Proceedings of the China Cancer Academic Conference 2008 of TCM & National TCM Academic Conference of Famous Doctors, pp. 118–120, Beijing, China, 2008.

[10] D. Li, L. Zhuangwei, W. Yiting et al., “Effect of matrine injections continuous infusion combined TACE treatment 30 cases with advanced liver cancer,” Journal of Practical Traditional Chinese Internal Medicine, vol. 24, no. 11, pp. 22–24, 2010.

[11] F. Jianwei, D. Yuan, and H. Wei, “Clinical observation on healing 40 cases advanced stage 14 gastric cancer with composite kushen injection and chemotherapy,” Journal of Emergency in Traditional Chinese Medicine, vol. 20, no. 1, pp. 152–153, 2011.

[12] G. Jianlin, L. Hong, and W. Liping, “Clinical observation on healing 63 case advanced stage NSCLC with composite kushen injection and NP program,” Journal of Xinjiang Medical University, vol. 29, no. 9, pp. 1018–1019, 2007.

[13] L. Yihang and L. Yinghui, “Clinical observation of gastric cancer treated by chemotherapy combined with Yanshu injection,” Jilin Medical Journal, vol. 31, no. 30, p. 5332, 2011.

[14] L. Yanru, “Research on non-small cell lung cancer treating with compound kushen injection and thermotherapy,” Chinese Journal of Modern Drug Application, vol. 7, no. 6, pp. 71–72, 2013.

[15] S. Jing and Y. Liping, “Clinical observation on late stage lung cancer treating with chemotherapy and compound kushen injection,” Traditional Chinese medicine in Inner Mongolia, vol. 11, pp. 13–14, 2012.

[16] S. Xinwen, “Addition of compound Kushen injection to vinorelbine plus cisplatin for patients with nonsmall cell lung cancer clinical observation,” Evaluation and Analysis of Drug-Use in Hospitals of China, vol. 12, no. 7, pp. 645–648, 2012.

[17] W. Huijuan, Z. Hongzhi, and L. Tao, “Clinical observation of late nonsmall-cell lung cancer treated by chemotherapy combined with yanshu injection,” Evaluation and Analysis of Drug-Use in Hospitals of China, vol. 6, no. 1, pp. 43–45, 2006.

[18] W. Shuo, L. Hongsheng, Z. Xinwen et al., “A randomized and multicenter clinical trial of compound matrine injection combined with hepatic artery interventional therapy in treatment of primary liver cancer,” Chinese Journal of Clinical Oncology and Rehabilitation, vol. 21, no. 3, pp. 331–335, 2014.

[19] X. Jinxu, Z. Shiyue, W. Airong et al., “Clinical observation of compound Kushen injection combined with FOLFOX regimen in treatment of advanced gastric cancer,” Chinese Archives of Traditional Chinese Medicine, vol. 31, no. 8, pp. 1812–1815, 2013.

[20] X. Xiaodong, Z. Zhendong, L. Dawei et al., “Clinical observation on improving the quality of life on late stage of colorectal carcinoma with compound matrine injections,” in Proceedings of the 10th National Combined Traditional Chinese and Western Medicine Tumor Academic Conference, pp. 294–296, Shenyang, China, 2006.

[21] Y. Jie, C. Xiang, Z. Xiaobing et al., “Clinical observation of colorectal cancer treating with compound kushen injection and chemotherapy,” Medical Recapitula, vol. 13, no. 23, pp. 1872–1874, 2007.

[22] Y. Zhengang and W. Bingzhe, “Efficacy of large dose of compound matrine injection combined chemotherapy for nonsmall-cell lung cancer,” Evaluation and Analysis of Drug-Use in Hospitals of China, vol. 12, no. 2, pp. 149–152, 2012.

[23] Z. Jincuo and S. Peng, “Clinical study on compound Sophora flavescens Ait com bined with chemotherapy for colorectal—cancer,” Journal of Clinical Medicine in Practice, vol. 16, no. 11, pp. 101–103, 2012.

[24] M. S. Walid, S. N. Donabue, D. M. Darmohray et al., “The fifth vital sign—what does it mean?” Pain Practice, vol. 8, no. 6, pp. 417–422, 2008.

[25] P. Sloan and R. Melzack, "Long-term patterns of morphine dosage and pain intensity among cancer patients," The Hospice Journal, vol. 14, no. 2, pp. 35–47, 1999.

[26] B. Cassileth, C. Trevisan, and J. Gubili, “Complementary therapies for cancer pain,” Current Pain and Headache Reports, vol. 11, no. 4, pp. 265–269, 2007.

[27] W. Wang, R. L. You, W. J. Qin et al., “Anti-tumor activities of active ingredients in Compound Kushen Injection,” Acta Pharmacologica Sinica, vol. 36, no. 6, pp. 676–679, 2015.

[28] B. Yanju, L. Yang, B. Hua et al., “A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain,” Supportive Care in Cancer, vol. 22, no. 3, pp. 825–836, 2014.

[29] Q. Sun, W. Ma, Y. Gao, W. Zheng, B. Zhang, and Y. Peng, “Meta-analysis: therapeutic effect of transcatheter arterial chemoembolization combined with compound kushen injection in hepatocellular carcinoma,” African Journal of Traditional, Complementary, and Alternative Medicines, vol. 9, no. 2, pp. 178–188, 2012.

[30] K. F. Schulz, D. G. Altman, D. Moher, and The CONSORT Group. “CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials,” PLoS Medicine, vol. 7, no. 3, Article ID e1000251, 2010.